

CURRICULUM VITAE

Name: **GIUSEPPE ALBERTO MARIA PALUMBO**

Place and date of birth: Catania, 2 Maggio 1965

Familial Status: Married, 2 sons

Actual position: Associate Professor of Hematology
University of Catania

Work address: UO di Ematologia con TMO
AOU "Policlinico-V.Emanuele"
PO Rodolico - Pad. 8
Via S. Sofia, 78
95123 CATANIA

Phone: 095-378.1960/378.1987

Home address: Via Anfuso, 16
95126 CATANIA

Phone: 095 – 518.7817

e-mail: ga.palumbo@tiscali.it
palumbo.ga@gmail.com

Medical Licence: CT9591 since the 15th of February, 1990

CAREER AND DEGREES

- College Degree (Maturità Classica) 1983
- First Certificate in English,
University of Cambridge, UK 1983
- Certificate of Proficiency in English,
University of Cambridge, UK 1984
- Attending Student, Istituto di Chimica Biologica,
Facoltà di Medicina e Chirurgia, Università di Catania 1984/85
- Visiting student, Surgery Clinic of
Pomeranian Medical Academy Szczecin, Poland 1986
- Visiting student, Gynecological Department of
Medical Academy in Szczecin, Poland 1986
- Visiting student in Warsaw, Medical Academy, Poland 1987
- Visiting student, Clinic of Internal Medicine
of the Medical Academy Szczecin, Poland 1987
- Winner Prize Toscano-Scuderi,
Facoltà di Medicina e Chirurgia
Università degli Studi di Catania 1987/88
- Attending Student, Istituto di Farmacologia,
Facoltà di Medicina e Chirurgia,
Università degli Studi di Catania. 1988/89
- Attending, Stage of Informatics,
IBM, Novedrate (MI) 1989
- M.D. Degree
Magna cum laude,
Università degli Studi di Catania 1989
- Medical Officer,
Corpo Sanitario Aeronautico (CSA),
Aeronautica Militare Italiana 1991
- Writer for medical-scientific journals,
(Corriere Medico, Cardio, Brain) 1991-93
- Residency Degree in Allergology and Clinical Immunology
Magna cum laude,
Università degli Studi di Milano 1992
- Winner, Grant for Scientific Research
to be done abroad,
Università degli Studi di Milano 1992
- Visiting Scientist, DNAX Research
Institute of Molecular and Cellular Biology,
Human Immunology Department,
Palo Alto, CA, U.S.A. 1992
- Visiting doctor, Cattedra di Ematologia,
Università degli Studi di Catania 1993-97

- Winner, Prize "Santella Massimino" -
Fondazione Catanese per lo Studio e la Cura
delle Malattie Neoplastiche del Sangue 1993
- Visiting Scientist, Hadassah Hospital,
Department of Hematology, Jerusalem, Israel 1994
- Winner, Grant European
School of Oncology (ESO) to attend
1st Educational Forum on Leukemias 1994
- Visiting Scientist, Hadassah Hospital,
Department of Hematology, Jerusalem, Israel 1996
- Residency Degree in Hematology
Magna cum laude,
Università degli Studi di Catania 1996
- Visiting Scientist, Department of Immunology,
Kochi University Japan 1997
- Hematology Stage,
Hammersmith Hospital, London, UK 2001
- Ph.D. in Experimental Pathology and Hematology 2002
- Hematology Stage,
University of Chicago, USA 2004
- Associate Professor of Hematology
University of Catania, Italy 2017
- Head of the Postgraduate School of Hematology
University of Catania, Italy 2018/2022

SCIENTIFIC SOCIETY MEMBERSHIP

- International Society for NeuroImmunoModulation (ISNIM). 1989-96
- Società Italiana di NeuroImmunoModulazione. 1992-96
- **Società Italiana di Ematologia (SIE) 1994...**
- **Società Italiana di Ematologia Sperimentale (SIES) 1998...**

RESEARCH ACTIVITY

- Studies on correlations between Nervous, Endocrin and Immunity systems and cooperation between all these systems with Reproductive system. Results were discussed in M.D. thesis and presented at national and international meetings and in papers on scientific international journals.
- Studies on mechanisms involved in allergic immunoflogosis, with special focus on immune system cells and on the role played by PAF. Results were discussed in Residency thesis in

Allergology and Clinical Immunology and presented at national and international meetings and in papers on scientific international journals.

- Studies on α - e β -thalassemias in Eastern Sicily. Correlations between phenotype and genotype. Measurement of incidence of different genotypes of α -thalassemia ($-\alpha$)^{20.5}, - - Med, - $\alpha^{3.7}$, - $\alpha^{4.2}$, $\alpha\alpha\alpha$). These studies were done using molecular biology techniques, such as PCR and Southern Blot, and were supported by Research Grants on Thalassemia from Regione Sicilia.

- In vitro chemosensitivity studies on fresh cells isolated from patients affected by acute and chronic leukemias and also on cell lines with several available and experimental drugs (fludarabine, 2-CDA, gemcytabine, mithoxantrone, vinca alkaloids, anthracyclins, taxol, topotecan, tyrphostins). Results were discussed in Residency thesis in Hematology and presented at national and international meetings and in papers on scientific international journals.

- Studies on production and release of cytokines both in physiological and pathological conditions, using molecular biology techniques, such as the Real-Time Polymerase Chain Reaction (PCR) semiquantitativa. Results were discussed in Ph.D. thesis in Experimental Pathology and Hematology and will be submitted to international peer-reviewed journals.

- Studies on minimal residual disease (MRD) detection in patients affected by leukemia, lymphoma or myeloma with molecular techniques. Results of these studies, which are ongoing with new techniques such as the Real-Time PCR, were published in international peer-reviewed journals.

- Studies on methylation status of gene promoters (in particular of *abl* gene) in Philadelphia chromosome leukemias (chronic myeloid leukemias and some acute lymphoblastic leukemias). Results of these studies, which are ongoing with new techniques such as the Real-Time PCR, were published in international peer-reviewed journals.

- Studies on the role of some genetic polymorphisms which may influence immune response and, in particular the antibody-dependent cell mediated cytotoxicity (ADCC) and the response to specific anticancer drugs such as monoclonal antibodies. Results of these studies, that are still ongoing, were presented at national and international meetings and and will be submitted to international peer-reviewed journals.

OTHER ACTIVITIES

- He participates in several activities of the Institute of Hematology, University of Catania. He held numerous seminars on oncological hematology and on molecular biology applied to Hematology, both for research and for diagnostic purposes. He gives his tutorship to M.D. and M.S. students and to Hematology Residents, also helping them in preparing thesis work.

- He has participated as invited speaker at several courses for M.D., M.S. and pharmaceutical company personnel.

- He has been in organizing and scientific secretariat of several Courses and Meetings held in Catania in the field of Hematology.

- He takes care of several patients affected by onco-hematological disorders, in all steps of their disease (diagnosis, therapy, follow-up).

- He is Head of the Molecular Biology Laboratory of the Hematology Department, Ospedale Ferrarotto, Catania.

- He is responsible of the web site of the Department of Hematology, Ospedale Ferrarotto, Catania (www.ematologiacatania.it).

- He is founder member of the Associazione Italiana contro le Leucemie (AIL) – Sezione di Catania and active member of its Executive Committee.

PAPERS IN EXTENSO INDEXED IN MEDLINE

157. Duminuco A, Nardo A, Garibaldi B, Vetro C, Longo A, Giallongo C, Di Raimondo F, Palumbo GA. **Prediction of Survival and Prognosis Migration from Gold-Standard Scores in Myelofibrosis Patients Treated with Ruxolitinib Applying the RR6 Prognostic Model in a Monocentric Real-Life Setting.** J Clin Med. 2022 Dec 14;11(24):7418. doi: 10.3390/jcm11247418.PMID: 36556033

156. Palumbo GA, Breccia M, Baratè C, Bonifacio M, Elli EM, Iurlo A, Pugliese N, Rossi E, Guglielmelli P, Palandri F. **Management of polycythemia vera: A survey of treatment patterns in Italy.** Eur J Haematol. 2022 Nov 1. doi: 10.1111/ejh.13889. Online ahead of print.PMID: 36319575

155. Carota G, Distefano A, Spampinato M, Giallongo C, Broggi G, Longhitano L, Palumbo GA, Parenti R, Caltabiano R, Giallongo S, Di Rosa M, Polosa R, Bramanti V, Vicario N, Li Volti G, Tibullo D. **Neuroprotective Role of α -Lipoic Acid in Iron-Overload-Mediated Toxicity and Inflammation in In Vitro and In Vivo Models.** Antioxidants (Basel). 2022 Aug 18;11(8):1596. doi: 10.3390/antiox11081596.PMID: 36009316

154. Breccia M, Palandri F, Guglielmelli P, Palumbo GA, Malato A, Mendicino F, Ricco A, Sant'Antonio E, Tiribelli M, Iurlo A. **Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance.** Curr Oncol. 2022 Jul 15;29(7):4970-4980. doi: 10.3390/curroncol29070395.PMID: 35877255

153. Duminuco A, Maugeri C, Parisi M, Mauro E, Fiumara PF, Randazzo V, Salemi D, Agueli C, Palumbo GA, Santoro A, Di Raimondo F, Vetro C. **Target Therapy for Extramedullary Relapse of FLT3-ITD Acute Myeloid Leukemia: Emerging Data from the Field.** Cancers (Basel). 2022 Apr 27;14(9):2186. doi: 10.3390/cancers14092186.PMID: 35565314

152. Romano A, Parrinello NL, Barchitta M, Manuele R, Puglisi F, Maugeri A, Barbato A, Triolo AM, Giallongo C, Tibullo D, La Ferla L, Botta C, Siragusa S, Iacobello C, Montineri A, Volti GL, Agodi A, Palumbo GA, Di Raimondo F. **In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection.** Sci Rep. 2022 May 4;12(1):7237. doi: 10.1038/s41598-022-11157-0.PMID: 35508575

151. Duminuco A, Maugeri C, Parisi M, Mauro E, Fiumara PF, Randazzo V, Salemi D, Agueli C, Palumbo GA, Santoro A, Di Raimondo F, Vetro C. **Target Therapy for Extramedullary Relapse of FLT3-ITD Acute Myeloid Leukemia: Emerging Data from the Field.** Cancers (Basel). 2022 Apr 27;14(9):2186. doi: 10.3390/cancers14092186.PMID: 35565314

150. Liso A, Venuto S, Coda ARD, Giallongo C, Palumbo GA, Tibullo D. **IGFBP-6: At the Crossroads of Immunity, Tissue Repair and Fibrosis.** Int J Mol Sci. 2022 Apr 14;23(8):4358. doi: 10.3390/ijms23084358.PMID: 35457175

149. Scandura G, Giallongo C, Puglisi F, Romano A, Parrinello NL, Zuppelli T, Longhitano L, Giallongo S, Di Rosa M, Musumeci G, Motterlini R, Foresti R, Palumbo GA, Li Volti G, Di Raimondo F, Tibullo D. **TLR4 Signaling and Heme Oxygenase-1/Carbon Monoxide Pathway Crosstalk Induces Resiliency of Myeloma Plasma Cells to Bortezomib Treatment.** Antioxidants (Basel). 2022 Apr 12;11(4):767. doi: 10.3390/antiox11040767.PMID: 35453452

148. Palandri F, Bartoletti D, Iurlo A, Bonifacio M, Abruzzese E, Caocci G, Elli EM, Auteri G, Tiribelli M, Polverelli N, Miglino M, Heidel FH, Tieghi A, Benevolo G, Beggiano E, Fava C, Cavazzini F, Pugliese N, Binotto G, Bosi C, Martino B, Crugnola M, Ottaviani E, Micucci G, Trawinska MM, Cuneo A, Bocchia M, Krampera M, Pane F, Lemoli RM, Cilloni D, Vianelli N, Cavo M, [Palumbo GA](#), Breccia M.

Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis.

Cancer. 2022 Jul 1;128(13):2449-2454. doi: 10.1002/cncr.34216. Epub 2022 Apr 1. PMID: 35363892

147. Vetro C, Duminuco A, Gozzo L, Maugeri C, Parisi M, Brancati S, Longo L, Vitale DC, Romano GL, Ciuni R, Mauro E, Fiumara PF, [Palumbo GAM](#), Drago F, Di Raimondo F.

Pegylated Asparaginase-Induced Liver Injury: A Case-Based Review and Data From Pharmacovigilance.

J Clin Pharmacol. 2022 Mar 27. doi: 10.1002/jcph.2052. PMID: 35342960

146. Duminuco A, Vetro C, Maugeri C, Mauro E, [Palumbo GAM](#), Parisi MS, Esposito B, Giuliano G, Romano A, Di Raimondo F.

Saprochete capitata: Emerging Infections from Uncommon Microorganisms in Hematological Diseases.

Hematol Rep. 2022 Mar 24;14(2):67-72. doi: 10.3390/hematolrep14020011. PMID: 35466175

145. Duminuco A, Vetro C, Markovic U, Di Raimondo F, [Palumbo GAM](#).

VEXAS-like syndrome: a potential new entity?

Ann Hematol. 2022 Mar 22. doi: 10.1007/s00277-022-04818-7.

144. Vetro C, Di Giacomo V, Mannina D, Magrin S, Mulè A, Mitra ME, Siragusa S, Duminuco A, Garibaldi B, Vadalà MCE, Di Raimondo F, [Palumbo GA](#).

Response Assessment to Erythropoietin-Zeta (Epo-Alpha Biosimilar) Therapy in Low-Risk Myelodysplastic Syndromes.

J Clin Med. 2022 Mar 17;11(6):1665. doi: 10.3390/jcm11061665.

143. D'Amico E, Zanghì A, Parrinello NL, Romano A, [Palumbo GA](#), Chisari CG, Toscano S, Raimondo FD, Zappia M, Patti F.

Immunological Subsets Characterization in Newly Diagnosed Relapsing-Remitting Multiple Sclerosis.

Front Immunol. 2022 Feb 22;13:819136. doi: 10.3389/fimmu.2022.819136. eCollection 2022.

142. Romano A, Cerchione C, Conticello C, Filetti S, Bulla A, Chiarenza A, Del Fabro V, Leotta S, Markovic U, Motta G, Parisi M, Stagno F, [Palumbo GA](#), Di Raimondo F.

Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 Infection.

Cancers 2022 Feb 24;14(5):1173. doi: 10.3390/cancers14051173.

141. Elli EM, Di Veroli A, Bartoletti D, Iurlo A, Carosino I, Benevolo G, Abruzzese E, Bonifacio M, Bergamaschi M, Polverelli N, Caramella M, Cilloni D, Tiribelli M, Pugliese N, Caocci G, Crisà E, Porrini R, Markovic U, Renso R, Auteri G, Cattaneo D, Trawinska MM, Scaffidi L, Biale L, Bucelli C, Breccia M, Gambacorti-Passerini C, [Palumbo GA](#), Latagliata R, Palandri F

Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL study.

Br J Haematol. 2022 Feb 8. doi: 10.1111/bjh.18057

140. Milone G, Bellofiore C, Leotta S, Milone GA, Cupri A, Duminuco A, Garibaldi B, [Palumbo G](#).

Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: A Review Based on Physiopathology.

J Clin Med. 2022 Jan 26;11(3):623. doi: 10.3390/jcm11030623. PMID: 35160072

139. Giallongo C, Dulcamare I, Tibullo D, Del Fabro V, Vicario N, Parrinello N, Romano A, Scandura G, Lazzarino G, Conticello C, Li Volti G, Amorini AM, Musumeci G, Di Rosa M, Polito F, Oteri R, Aguenouz M, Parenti R, Di Raimondo F, [Palumbo GA](#).

CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment.

Oncogenesis. 2022 Jan 21;11(1):6. doi: 10.1038/s41389-022-00380-z. PMID: 35064098

138. Longhitano L, Tibullo D, Vicario N, Giallongo C, La Spina E, Romano A, Lombardo S, Moretti M, Masia F, Coda ARD, Venuto S, Fontana P, Parenti R, Li Volti G, Di Rosa M, [Palumbo GA](#), Liso A.
IGFBP-6/sonic hedgehog/TLR4 signalling axis drives bone marrow fibrotic transformation in primary myelofibrosis.

Aging 2021 Dec 14;13(23):25055-25071. doi: 10.18632/aging.203779. Epub 2021 Dec 14. PMID: 34905501

137. Duminuco A, Mauro E, [Palumbo GAM](#), Garibaldi B, Parisi M, Di Raimondo F, Maugeri C, Vetro C
Therapeutic innovation for multi-resistant candidemics: Synergy of isavuconazole and caspofungin association.

Hematol Rep. 2021 Nov 26;13(4):9329. doi: 10.4081/hr.2021.9329. eCollection 2021 Nov 26. PMID: 35070221

136. Gozzo L, Vetro C, Brancati S, Longo L, Vitale DC, Romano GL, Mauro E, Fiumara PF, Maugeri C, Parisi MS, Dulcamare I, Garibaldi B, Duminuco A, [Palumbo GA](#), Di Raimondo F, Drago F.

Off-Label Use of Venetoclax in Patients with Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database.

Front Pharmacol. 2021 Nov 11;12:748766. doi: 10.3389/fphar.2021.748766. eCollection 2021. PMID: 34899303

135. [Palumbo GA](#), Galimberti S, Barcellini W, Cilloni D, Di Renzo N, Elli EM, Finelli C, Maurillo L, Ricco A, Musto P, Russo R, Latagliata R

From Biology to Clinical Practice: Iron Chelation Therapy with Deferasirox.

Front Oncol. 2021 Oct 6;11:752192. doi: 10.3389/fonc.2021.752192. eCollection 2021.

134. Guglielmelli P, Palandri F, Selleri C, Cilloni D, Mendicino F, Mazza P, Pastore D, [Palumbo GA](#), Santoro M, Pavone V, Impera S, Morelli M, Coco P, Valsecchi D, Passamonti F, Breccia M.

Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI).

Leuk Lymphoma. 2021 Sep 15:1-10. doi: 10.1080/10428194.2021.1969388. PMID: 34521299

133. Sonneveld P, Dimopoulos MA, Beksac M, van der Holt B, Aquino S, Ludwig H, Zweegman S, Zander T, Zamagni E, Wester R, Hajek R, Pantani L, Dozza L, Gay F, Cafro A, De Rosa L, Morelli A, Gregersen H, Gulbrandsen N, Cornelisse P, Troia R, Oliva S, van de Velden V, Wu K, Ypma PF, Bos G, Levin MD, Pour L, Driessen C, Broijl A, Croockewit A, Minnema MC, Waage A, Hveding C, van de Donk NWCJ, Offidani M, [Palumbo GA](#), Spencer A, Boccadoro M, Cavo M.

Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma.

J Clin Oncol. 2021 Sep 14;JCO2101045. doi: 10.1200/JCO.21.01045. PMID: 34520219

132. Oliva EN, Latagliata R, Sabattini E, Mammi C, Cuzzola M, D'Errigo MG, Cannatà MC, Bova I, Capodanno I, [Palumbo GA](#), Pane F, Reda G, Fianchi L, Riva M, Poloni A.

Accuracy of bone marrow histochemical TP53 expression compared to the detection of TP53 somatic mutations in patients with myelodysplastic syndromes harbouring a del5q cytogenetic abnormality.

Am J Blood Res. 2021 Aug 15;11(4):417-426. eCollection 2021. PMID: 34540351

131. Botta C, Martino EA, Conticello C, Mendicino F, Vigna E, Romano A, [Palumbo GA](#), Cerchione C, Martinelli G, Morabito F, Di Raimondo F, Gentile M.

Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens.

Front Oncol. 2021 Apr 14;11:643490. doi: 10.3389/fonc.2021.643490. eCollection 2021. PMID: 33937048

130. Palandri F, Tiribelli M, Breccia M, Bartoletti D, Elli EM, Benevolo G, Martino B, Cavazzini F, Tieghi A, Iurlo A, Abruzzese E, Pugliese N, Binotto G, Caocci G, Auteri G, Cattaneo D, Trawinska MM, Stella R, Scaffidi L, Polverelli N, Micucci G, Masselli E, Crugnola M, Bosi C, Heidel FH, Latagliata R, Pane F, Cuneo A, Krampera M, Semenzato G, Lemoli RM, Cavo M, Vianelli N, Bonifacio M, [Palumbo GA](#).

Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome.

Cancer. 2021 Apr 1. doi: 10.1002/cncr.33541. PMID: 33794557

129. Gamper EM, Cottone F, Sommer K, Norman R, King M, Breccia M, Caocci G, Patriarca A, [Palumbo GA](#), Stauder R, Niscola P, Platzbecker U, Caers J, Vignetti M, Efficace F.

The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L.

J Clin Epidemiol. 2021 Mar 20;137:31-44. doi: 10.1016/j.jclinepi.2021.03.015. PMID: 33753228

128. Benevolo G, Elli EM, Bartoletti D, Latagliata R, Tiribelli M, Heidel FH, Cavazzini F, Bonifacio M, Crugnola M, Binotto G, D'Addio A, Tieghi A, Bergamaschi M, Caocci G, Polverelli N, Bossi E, Auteri G, Carosino I, Catani L, Cuneo A, Krampera M, Lanza F, Lemoli RM, Vianelli N, Breccia M, Palumbo GA, Cavo M, Palandri F.

Impact of comorbidities and body mass index on the outcome of polycythemia vera patients.

Hematol Oncol. 2021 Feb 15. doi: 10.1002/hon.2843.

127. Spampinato M, Giallongo C, Romano A, Longhitano L, La Spina E, Avola R, Scandura G, Dulcamare I, Bramanti V, Di Rosa M, Vicario N, Parenti R, Li Volti G, Tibullo D, Palumbo GA.

Focus on Osteosclerotic Progression in Primary Myelofibrosis.

Biomolecules. 2021 Jan 19;11(1):122. doi: 10.3390/biom11010122.PMID: 33477816

126. Palandri F, Palumbo GA, Elli EM, Polverelli N, Benevolo G, Martino B, Abruzzese E, Tiribelli M, Tieghi A, Latagliata R, Cavazzini F, Bergamaschi M, Binotto G, Crugnola M, Isidori A, Caocci G, Heidel F, Pugliese N, Bosi C, Bartoletti D, Auteri G, Cattaneo D, Scaffidi L, Trawinska MM, Stella R, Ciantia F, Pane F, Cuneo A, Krampera M, Semenzato G, Lemoli RM, Iurlo A, Vianelli N, Cavo M, Breccia M, Bonifacio M.

Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis.

Blood Cancer J. 2021 Jan 7;11(1):4. doi: 10.1038/s41408-020-00392-1.PMID: 33414394

125. Stella S, Massimino M, Manzella L, Pennisi MS, Tirrò E, Romano C, Vitale SR, Puma A, Tomarchio C, Gregorio SD, Palumbo GA, Vigneri P.

Molecular Pathogenesis and Treatment Perspectives for Hypereosinophilia and Hypereosinophilic Syndromes.

Int J Mol Sci. 2021 Jan 6;22(2):486. doi: 10.3390/ijms22020486.PMID: 33418988

124. Polverelli N, Elli EM, Abruzzese E, Palumbo GA, Benevolo G, Tiribelli M, Bonifacio M, Tieghi A, Caocci G, D'Adda M, Bergamaschi M, Binotto G, Heidel FH, Cavazzini F, Crugnola M, Pugliese N, Bosi C, Isidori A, Bartoletti D, Auteri G, Latagliata R, Gandolfi L, Martino B, Scaffidi L, Cattaneo D, D'Amore F, Trawinska MM, Stella R, Markovic U, Catani L, Pane F, Cuneo A, Krampera M, Semenzato G, Lemoli RM, Vianelli N, Breccia M, Russo D, Cavo M, Iurlo A, Palandri F.

Second primary malignancy in myelofibrosis patients treated with ruxolitinib.

Br J Haematol. 2021 Apr;193(2):356-368. doi: 10.1111/bjh.17192. Epub 2020 Nov 21.PMID: 3322219.

123. Barbato A, Scandura G, Puglisi F, Cambria D, La Spina E, Palumbo GA, Lazzarino G, Tibullo D, Di Raimondo F, Giallongo C, Romano A.

Mitochondrial Bioenergetics at the Onset of Drug Resistance in Hematological Malignancies: An Overview.

Front Oncol. 2020 Dec 21;10:604143. doi: 10.3389/fonc.2020.604143. eCollection 2020.PMID: 33409153

122. Mossuto S, Attardi E, Alesiani F, Angelucci E, Balleari E, Bernardi M, Binotto G, Bosi C, Calvisi A, Capodanno I, Carbone A, Castelli A, Cerrano M, Ciancia R, Cilloni D, Clavio M, Clissa C, Crisà E, Crugnola M, Della Porta MG, Di Renzo N, Di Veroli A, Fattizzo R, Fava C, Fenu S, Ferrara IL, Fianchi L, Fili C, Finelli C, Gai V, Frattini F, Gaidano V, Guaragna G, Gumenyuk S, Latagliata R, Mancini S, Messa E, Molteni A, Musto P, Niscola P, Oliva E, Palumbo GA, Pelizzari A, Pilo F, Poloni A, Riva M, Rivellini F, Sarlo C, Sciumé M, Secchi R, Selleri C, Tafuri A, Santini V.

SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot from early Italian experience.

Hemasphere. 2020 Sep 23;4(5):e483. doi: 10.1097/HS9.0000000000000483. PMID: 33062948; PMCID: PMC7523798.

121. Camiolo G, Barbato A, Giallongo C, Vicario N, Romano A, Parrinello NL, Parenti R, Sandoval JC, García-Moreno D, Lazzarino G, Avola R, Palumbo GA, Mulero V, Li Volti G, Tibullo D, Di Raimondo F.

Iron regulates myeloma cell/macrophage interaction and drives resistance to bortezomib.

Redox Biol. 2020 Sep;36:101611. doi: 10.1016/j.redox.2020.101611. Epub 2020 Jun 24.PMID: 32863212

120. Longhitano L, Li Volti G, Giallongo C, Spampinato M, Barbagallo I, Di Rosa M, Romano A, Avola R, Tibullo D, Palumbo GA.
The Role of Inflammation and Inflammasome in Myeloproliferative Disease.
J Clin Med. 2020 Jul 22;9(8):2334. doi: 10.3390/jcm9082334.PMID: 32707883
119. Giallongo C, Tibullo D, Puglisi F, Barbato A, Vicario N, Cambria D, Parrinello NL, Romano A, Conticello C, Forte S, Parenti R, Amorini AM, Lazzarino G, Li Volti G, Palumbo GA, Di Raimondo F.
Inhibition of TLR4 Signaling Affects Mitochondrial Fitness and Overcomes Bortezomib Resistance in Myeloma Plasma Cells.
Cancers (Basel). 2020 Jul 22;12(8):1999. doi: 10.3390/cancers12081999.PMID: 32707760
118. Caocci G, Vignetti M, Patriarca A, Breccia M, Platzbecker U, Palumbo GA, Stauder R, Cottone F, Petranovic D, Voso MT, Tafuri A, Invernizzi R, Caers J, Luppi M, La Nasa G, Niscola P, Efficace F.
High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity.
Int J Hematol. 2020 Aug;112(2):141-146. doi: 10.1007/s12185-020-02920-y. Epub 2020 Jun 25. PMID: 32588394
117. Puglisi F, Parrinello NL, Giallongo C, Cambria D, Camiolo G, Bellofiore C, Conticello C, Del Fabro V, Leotta V, Markovic U, Sapienza G, Barbato A, Scalese S, Tibullo D, Brundo MV, Palumbo GA, Di Raimondo F, Romano A.
Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy Via STAT3.
Int J Mol Sci. 2019 Jul 19;20(14):3548. doi: 10.3390/ijms20143548.PMID: 32565533
116. Malato A, Rossi E, Palumbo GA, Guglielmelli P, Pugliese N.
Drug-Related Cutaneous Adverse Events in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Literature Review.
Int J Mol Sci. 2020 May 30;21(11):3900. doi: 10.3390/ijms21113900.PMID: 32486130
115. Longhitano L, Tibullo D, Giallongo C, Lazzarino G, Tartaglia N, Galimberti S, Li Volti G, Palumbo GA, Liso A.
Proteasome Inhibitors as a Possible Therapy for SARS-CoV-2.
Int J Mol Sci. 2020 May 20;21(10):3622. doi: 10.3390/ijms21103622.PMID: 32443911
114. Tibullo D, Giallongo C, Romano A, Vicario N, Barbato A, Puglisi F, Parenti R, Amorini AM, Wissam Saab M, Tavazzi B, Mangione R, Brundo MV, Lazzarino G, Palumbo GA, Volti GL, Raimondo FD, Lazzarino G.
Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells.
Biomolecules. 2020 Apr 30;10(5):696. doi: 10.3390/biom10050696.PMID: 32365811
113. Cavo M, Gay F, Beksac M, Pantani L, Petrucci MT, Dimopoulos MA, Dozza L, van der Holt B, Zweegman S, Oliva S, van der Velden VHJ, Zamagni E, Palumbo GA, Patriarca F, Montefusco V, Galli M, Maisnar V, Gamberi B, Hansson M, Belotti A, Pour L, Ypma P, Grasso M, Croockewit A, Ballanti S, Offidani M, Vincelli ID, Zambello R, Liberati AM, Andersen NF, Broijl A, Troia R, Pascarella A, Benevolo G, Levin MD, Bos G, Ludwig H, Aquino S, Morelli AM, Wu KL, Boersma R, Hajek R, Durian M, von dem Borne PA, Caravita di Toritto T, Zander T, Specchia G, Waage A, Gimsing P, Mellqvist UH, van Marwijk Kooy M, Minnema M, Mandigers C, Cafo AM, Palmas A, Carvalho S, Spencer A, Boccadoro M, Sonneveld P.
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30.PMID: 32359506
112. Di Rosa M, Giallongo C, Romano A, Tibullo D, Li Volti G, Musumeci G, Barbagallo I, Imbesi R, Castrogiovanni P, Palumbo GA.
Immunoproteasome Genes Are Modulated in CD34⁺ JAK2^{V617F} Mutated Cells from Primary Myelofibrosis Patients.

111. Palandri F, Breccia M, Tiribelli M, Bonifacio M, Benevolo G, Iurlo A, Elli EM, Binotto G, Tieghi A, Polverelli N, Martino B, Abruzzese E, Bergamaschi M, Heidel FH, Cavazzini F, Crugnola M, Bosi C, Isidori A, Auteri G, Forte D, Latagliata R, Griguolo D, Cattaneo D, Trawinska M, Bartoletti D, Krampera M, Semenzato G, Lemoli RM, Cuneo A, Di Raimondo F, Vianelli N, Cavo M, [Palumbo GA](#).

Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data.

Hematol Oncol. 2020 Apr 9. doi: 10.1002/hon.2737. [Epub ahead of print]

110. Efficace F, Cottone F, Oswald LB, Cella D, Patriarca A, Niscola P, Breccia M, Platzbecker U, [Palumbo GA](#), Caocci G, Stauder R, Ricco A, Petranovic D, Caers J, Luppi M, Fianchi L, Frairia C, Capodanno I, Follini E, Sarlo C, Fazi P, Vignetti M.

The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index.

Leukemia. 2020 Feb 21. doi: 10.1038/s41375-020-0746-8.

109. Romano A, Parrinello NL, Simeon V, Puglisi F, La Cava P, Bellofiore C, Giallongo C, Camiolo G, D'Auria F, Grieco V, Larocca F, Barbato A, Cambria D, La Spina E, Tibullo D, [Palumbo GA](#), Conticello C, Musto P, Di Raimondo F.

High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling.

Sci Rep. 2020 Feb 6;10(1):1983. doi: 10.1038/s41598-020-58859-x.

108. Tibullo D, Longo A, Vicario N, Romano A, Barbato A, Di Rosa M, Barbagallo I, Anfuso CD, Lupo G, Gulino R, Parenti R, Li Volti GL, [Palumbo GA](#), Di Raimondo FD, Giallongo C.

Ixazomib Improves Bone Remodeling and Counteracts sonic Hedgehog signaling Inhibition Mediated by Myeloma Cells.

Cancers (Basel). 2020 Jan 30;12(2). pii: E323. doi: 10.3390/cancers12020323.

107. Al-Ali HK, Grieshammer M, Foltz L, [Palumbo GA](#), Martino B, Palandri F, Liberati AM, le Coutre P, Garcia-Hernández C, Zaritsky A, Tavares R, Gupta V, Raanani P, Giraldo P, Hänel M, Damiani D, Sacha T, Bouard C, Paley C, Tiwari R, Mannelli F, Vannucchi AM.

Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.

Br J Haematol. 2020 Feb 4. doi: 10.1111/bjh.16462.

106. Palandri F, Breccia M, Bonifacio M, Polverelli N, Elli EM, Benevolo G, Tiribelli M, Abruzzese E, Iurlo A, Heidel FH, Bergamaschi M, Tieghi A, Crugnola M, Cavazzini F, Binotto G, Isidori A, Sgherza N, Bosi C, Martino B, Latagliata R, Auteri G, Scaffidi L, Griguolo D, Trawinska M, Cattaneo D, Catani L, Krampera M, Lemoli RM, Cuneo A, Semenzato G, Foà R, Di Raimondo F, Bartoletti D, Cavo M, [Palumbo GA](#), Vianelli N.

Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis.

Cancer. 2020 Mar 15;126(6):1243-1252. doi: 10.1002/cncr.32664. Epub 2019 Dec 20.

105. Breccia M, Baratè C, Benevolo G, Bonifacio M, Elli EM, Guglielmelli P, Maffioli M, Malato A, Mendicino F, [Palumbo GA](#), Pugliese N, Rossi E, Rumi E, Sant'Antonio E, Ricco A, Tiribelli M, Palandri F.

Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-world practice.

Ann Hematol. 2020 Jan;99(1):65-72. doi: 10.1007/s00277-019-03847-z. Epub 2019 Dec 12.

104. Elli EM, Baratè C, Mendicino F, Palandri F, [Palumbo GA](#).

Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib.

Front Oncol. 2019 Nov 7;9:1186. doi: 10.3389/fonc.2019.01186. eCollection 2019.

103. [Palumbo GA](#), Parrinello NL, Giallongo C, D'Amico E, Zanghì A, Puglisi F, Conticello C, Chiarenza A, Tibullo D, Raimondo FD, Romano A.

Monocytic Myeloid Derived Suppressor Cells in Hematological Malignancies.

Int J Mol Sci. 2019 Nov 1;20(21). pii: E5459. doi: 10.3390/ijms20215459.

102. D'Amico E, Zanghì A, Romano A, Sciandra M, Palumbo GA, Patti F.
The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis.
Cells. 2019 Sep 20;8(10). pii: E1114. doi: 10.3390/cells8101114.
101. Giallongo C, Tibullo D, Camiolo G, Parrinello NL, Romano A, Puglisi F, Barbato A, Conticello C, Lupo G, Anfuso CD, Lazzarino G, Li Volti G, Palumbo GA, Di Raimondo F.
TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma.
Cell Death Dis. 2019 Sep 20;10(10):704. doi: 10.1038/s41419-019-1959-5.
100. Romano A, Palumbo GA, Parrinello NL, Conticello C, Martello M, Terragna C.
Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives.
Front Oncol. 2019 Aug 20;9:699. doi: 10.3389/fo
99. Bereshchenko O, Lo Re O, Nikulenkov F, Flamini S, Kotaskova J, Mazza T, Le Pannéer MM, Buschbeck M, Giallongo C, Palumbo G, Li Volti G, Paziienza V, Cervinek L, Riccardi C, Krejci L, Pospisilova S, Stewart AF, Vinciguerra M.
Deficiency and haploinsufficiency of histone macroH2A1.1 in mice recapitulate hematopoietic defects of human myelodysplastic syndrome.
Clin Epigenetics. 2019 Aug 22;11(1):121. doi: 10.1186/s13148-019-0724-z.
98. Palumbo GA, Stella S, Pennisi MS, Piroso C, Fermo E, Fabris S, Cattaneo D, Iurlo A.
The Role of New Technologies in Myeloproliferative Neoplasms.
Front Oncol. 2019 Apr 26;9:321. doi: 10.3389/fonc.2019.00321. eCollection 2019.
97. Palandri F, Palumbo GA, Abruzzese E, Iurlo A, Polverelli N, Elli E, Bonifacio M, Bergamaschi M, Martino B, Tiribelli M, Benevolo G, Tieghi A, Sgherza N, Isidori A, Binotto G, Crugnola M, Heidele F, Cavazzini F, Bosi C, Auteri G, Cattaneo D, Foà R, Lemoli RM, Cuneo A, Krampera M, Bartoletti D, Cavo M, Vianelli N, Breccia M, Latagliata R.
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib.
Hematol Oncol. 2019 Apr 15. doi: 10.1002/hon.2619.
96. Pappalardo A, Currenti W, Ponzio R, Mellini G, Nicolosi D, Longhitano L, Tibullo D, Castorina S, Palumbo G.
Effects of micronised microencapsulated ferric pyrophosphate supplementation in patients with advanced cancer and iron deficiency: a single-centre cohort pilot study.
Blood Transfus. 2019 May;17(3):196-199. doi: 10.2450/2019.0181-18. Epub 2019 Feb 18.
95. Tirrò E, Massimino M, Romano C, Pennisi MS, Stella S, Vitale SR, Fidilio A, Manzella L, Parrinello NL, Stagno F, Palumbo GA, La Cava P, Romano A, Di Raimondo F, Vigneri PG.
Chk1 Inhibition Restores Inotuzumab Ozogamicin Cytotoxicity in CD22-Positive Cells Expressing Mutant p53.
Front Oncol. 2019 Feb 18;9:57. doi: 10.3389/fonc.2019.00057. eCollection 2019.
94. Romano A, Parrinello NL, Chiarenza A, Motta G, Tibullo D, Giallongo C, La Cava P, Camiolo G, Puglisi F, Palumbo GA, Di Raimondo F.
Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma.
Br J Haematol. 2019 Feb 15. doi: 10.1111/bjh.15801. [Epub ahead of print]
93. Camiolo G, Tibullo D, Giallongo C, Romano A, Parrinello NL, Musumeci G, Di Rosa M, Vicario N, Brundo MV, Amenta F, Ferrante M, Copat C, Avola R, Li Volti G, Salvaggio A, Di Raimondo F, Palumbo GA.
α-Lipoic Acid Reduces Iron-induced Toxicity and Oxidative Stress in a Model of Iron Overload.
Int J Mol Sci. 2019 Jan 31;20(3). pii: E609. doi: 10.3390/ijms20030609.

92. Palandri F, Palumbo GA, Iurlo A, Polverelli N, Benevolo G, Breccia M, Abruzzese E, Tiribelli M, Bonifacio M, Tieghi A, Isidori A, Martino B, Sgherza N, D'Adda M, Bergamaschi M, Crugnola M, Cavazzini F, Bosi C, Binotto G, Auteri G, Latagliata R, Ibatci A, Scaffidi L, Penna D, Cattaneo D, Soci F, Trawinska M, Russo D, Cuneo A, Semenzato G, Di Raimondo F, Aversa F, Lemoli RM, Heidel F, Reggiani MLB, Bartoletti D, Cavo M, Catani L, Vianelli N.

Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study.

Semin Hematol. 2018 Oct;55(4):248-255. doi: 10.1053/j.seminhematol.2018.05.013. Epub 2018 Jun 5.

91. Breccia M, Bartoletti D, Bonifacio M, Palumbo GA, Polverelli N, Abruzzese E, Bergamaschi M, Tieghi A, Tiribelli M, Iurlo A, Cavazzini F, Sgherza N, Binotto G, Isidori A, D'Adda M, Crugnola M, Bosi C, Heidel F, Molica M, Scaffidi L, Cattaneo D, Latagliata R, Auteri G, Lemoli RM, Fanin R, Russo D, Aversa F, Cuneo A, Semenzato G, Catani L, Cavo M, Vianelli N, Foà R, Palandri F.

Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib.

Ann Hematol. 2018 Dec 4. doi: 10.1007/s00277-018-3569-1. [Epub ahead of print]

90. Girmenia C, Candoni A, Delia M, Latagliata R, Molteni A, Oliva EN, Palumbo GA, Poloni A, Salutari P, Santini V, Voso MT, Musto P.

Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations.

Blood Rev. 2018 Oct 28. pii: S0268-960X(18)30069-9. doi: 10.1016/j.blre.2018.10.002. [Epub ahead of print] Review.

89. Palandri F, Palumbo GA, Bonifacio M, Breccia M, Latagliata R, Martino B, Polverelli N, Abruzzese E, Tiribelli M, Nicolosi M, Bergamaschi M, Tieghi A, Iurlo A, Sgherza N, Cavazzini F, Isidori A, Binotto G, Ibatci A, Crugnola M, Heidel F, Bosi C, Bartoletti D, Auteri G, Catani L, Cuneo A, Aversa F, Semenzato G, Cavo M, Vianelli N, Benevolo G.

Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients.

Leuk Res. 2018 Nov;74:86-88. doi: 10.1016/j.leukres.2018.10.001. Epub 2018 Oct 5.

88. Palandri F, Catani L, Bonifacio M, Benevolo G, Heidel F, Palumbo GA, Crugnola M, Abruzzese E, Bartoletti D, Polverelli N, Bergamaschi M, Tiribelli M, Iurlo A, Breccia M, Cavazzini F, Tieghi A, Binotto G, Isidori A, Martino B, D'Adda M, Bosi C, Sabattini E, Vitolo U, Aversa F, Ibatci A, Lemoli RM, Sgherza N, Cuneo A, Martinelli G, Semenzato G, Cavo M, Vianelli N, Sapienza MR, Latagliata R.

Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients.

Br J Haematol. 2018 Jul 16. doi: 10.1111/bjh.15497. [Epub ahead of print]

87. Crisà E, Cillonì D, Elli EM, Martinelli V, Palumbo GA, Pugliese N, Beggiato E, Frairia C, Cerrano M, Lanzarone G, Marchetti M, Mezzabotta M, Boccadoro M, Ferrero D.

The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib.

Br J Haematol. 2018 Jul 9. doi: 10.1111/bjh.15450. [Epub ahead of print]

86. Romano A, Parrinello NL, La Cava P, Tibullo D, Giallongo C, Camiolo G, Puglisi F, Parisi M, Piroso MC, Martino E, Conticello C, Palumbo GA, Di Raimondo F.

PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy.

Expert Rev Mol Diagn. 2018 May 3:1-9. doi: 10.1080/14737159.2018.1470929. [Epub ahead of print]

85. Isidori A, Borin L, Elli E, Latagliata R, Martino B, Palumbo G, Pilo F, Loscocco F, Visani G, Cianciulli P.

Iron toxicity - Its effect on the bone marrow.

Blood Rev. 2018 Apr 13. pii: S0268-960X(17)30150-9. doi: 10.1016/j.blre.2018.04.004. [Epub ahead of print]

84. Polverelli N, Palumbo GA, Binotto G, Abruzzese E, Benevolo G, Bergamaschi M, Tieghi A, Bonifacio M, Breccia M, Catani L, Tiribelli M, D'Adda M, Sgherza N, Isidori A, Cavazzini F, Martino B, Latagliata R, Crugnola M, Heidel F, Bosi C, Ibatci A, Soci F, Penna D, Scaffidi L, Aversa F, Lemoli RM, Vitolo U, Cuneo A, Russo D, Cavo M, Vianelli N, Palandri F.

Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients.

Hematol Oncol. 2018 Apr 6. doi: 10.1002/hon.2509. [Epub ahead of print]

83. Palandri F, Benevolo G, Iurlo A, Abruzzese E, Carella AM, Paoli C, Palumbo GA, Bonifacio M, Cilloni D, Andriani A, Guarini A, Turri D, Elli EM, Falcone A, Anaclerico B, Musto P, Di Renzo N, Tiribelli M, Zambello R, Spinosa C, Ricco A, Raucci L, Martino B, Annunziata M, Pascale S, Liberati AM, La Nasa G, Maffioli M, Breccia M, Pugliese N, Betti S, Giglio G, Cappuccio A, Reale L.

Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine-Results from the Italian 'Back to Life' project.

Qual Life Res. 2018 Mar 8. doi: 10.1007/s11136-018-1827-2. [Epub ahead of print]

82. Breccia M, Palandri F, Luciano L, Benevolo G, Bonifacio M, Caocci G, Castagnetti F, Palumbo GA, Iurlo A, Landi F.

Identification and assessment of frailty in older patients with chronic myeloid leukemia and myelofibrosis, and indications for tyrosine kinase inhibitor treatment.

Ann Hematol. 2018 May;97(5):745-754. doi: 10.1007/s00277-018-3258-0. Epub 2018 Feb 22. Review.

81. Romano A, Parrinello NL, Vetro C, Chiarenza A, Cerchione C, Ippolito M, Palumbo GA, Di Raimondo F.

Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy.

Ann Hematol. 2018 Feb 14. doi: 10.1007/s00277-018-3276-y. [Epub ahead of print]

80. Efficace F, Cottone F, Abel G, Niscola P, Gaidano G, Bonnetain F, Anota A, Caocci G, Cronin A, Fianchi L, Breccia M, Stauder R, Platzbecker U, Palumbo GA, Luppi M, Invernizzi R, Bergamaschi M, Borin L, Di Tucci AA, Zhang H, Sprangers M, Vignetti M, Mandelli F.

Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes.

Cancer. 2018 Mar 15;124(6):1251-1259. doi: 10.1002/cncr.31193. Epub 2017 Dec 12.

79. Giallongo C, Parrinello NL, La Cava P, Camiolo G, Romano A, Scalia M, Stagno F, Palumbo GA, Avola R, Li Volti G, Tibullo D, Di Raimondo F.

Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib.

J Cell Mol Med. 2018 Feb;22(2):1070-1080. doi: 10.1111/jcmm.13326. Epub 2017 Dec 8.

78. Maffei R, Fiorcari S, Martinelli S, Benatti S, Bulgarelli J, Rizzotto L, Debbia G, Santachiara R, Rigolin GM, Forconi F, Rossi D, Laurenti L, Palumbo GA, Vallisa D, Cuneo A, Gaidano G, Luppi M, Marasca R.

Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide.

Leuk Lymphoma. 2018 Feb;59(2):423-433. doi: 10.1080/10428194.2017.1339872. Epub 2017 Jun 22.

77. Palandri F, Palumbo GA, Bonifacio M, Tiribelli M, Benevolo G, Martino B, Abruzzese E, D'Adda M, Polverelli N, Bergamaschi M, Tieghi A, Cavazzini F, Ibatici A, Crugnola M, Bosi C, Latagliata R, Di Veroli A, Scaffidi L, de Marchi F, Cerqui E, Anaclerico B, De Matteis G, Spinsanti M, Sabattini E, Catani L, Aversa F, Di Raimondo F, Vitolo U, Lemoli RM, Fanin R, Merli F, Russo D, Cuneo A, Bacchi Reggiani ML, Cavo M, Vianelli N, Breccia M.

Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis.

Oncotarget. 2017 Jun 27;8(45):79073-79086. doi: 10.18632/oncotarget.18674. eCollection 2017 Oct 3.

76. Palandri F, Tiribelli M, Benevolo G, Tieghi A, Cavazzini F, Breccia M, Bergamaschi M, Sgherza N, Polverelli N, Crugnola M, Isidori A, Binotto G, Heidel FH, Buccisano F, Martino B, Latagliata R, Spinsanti M, Kallenberg L, Palumbo GA, Abruzzese E, Scaffidi L, Cuneo A, Cavo M, Vianelli N, Bonifacio M.

Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study.

Hematol Oncol. 2017 May 17. doi: 10.1002/hon.2429. [Epub ahead of print]

75. Latagliata R, Polverelli N, Tieghi A, [Palumbo GA](#), Breccia M, Sabattini E, Villari L, Riminucci M, Valli R, Catani L, Alimena G, Ottaviani E, Fama A, Martinelli G, Perricone M, Spinsanti M, Cavo M, Vianelli N, Palandri F.

Comparison of JAK2^{V617F}-positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology.

Hematol Oncol. 2017 May 16. doi: 10.1002/hon.2430. [Epub ahead of print]

74. Romano A, Giallongo C, La Cava P, Parrinello NL, Chiechi A, Vetro C, Tibullo D, Di Raimondo F, Liotta LA, Espina V, [Palumbo GA](#).

Proteomic Analysis Reveals Autophagy as Pro-Survival Pathway Elicited by Long-Term Exposure with 5-Azacitidine in High-Risk Myelodysplasia.

Front Pharmacol. 2017 Apr 26;8:204. doi: 10.3389/fphar.2017.00204. eCollection 2017.

73. Oliva EN, Alati C, Santini V, Poloni A, Molteni A, Niscola P, Salvi F, Sanpaolo G, Balleari E, Germing U, Fenaux P, Stamatoullas A, [Palumbo GA](#), Salutari P, Impera S, Avanzini P, Cortelezzi A, Liberati AM, Carluccio P, Buccisano F, Voso MT, Mancini S, Kulasekararaj A, Morabito F, Bocchia M, Cufari P, Spiriti MA, Santacaterina I, D'Errigo MG, Bova I, Zini G, Latagliata R.

Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.

Lancet Haematol. 2017 Mar;4(3):e127-e136. doi: 10.1016/S2352-3026(17)30012-1. Epub 2017 Feb 3

72. Giallongo C, Romano A, Parrinello NL, La Cava P, Brundo MV, Bramanti V, Stagno F, Vigneri P, Chiarenza A, [Palumbo GA](#), Tibullo D, Di Raimondo F.

Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients.

PLoS One. 2016 Jul 8;11(7):e0158392. doi: 10.1371/journal.pone.0158392. eCollection 2016.

71. Giallongo C, Tibullo D, Parrinello NL, La Cava P, Di Rosa M, Bramanti V, Di Raimondo C, Conticello C, Chiarenza A, [Palumbo GA](#), Avola R, Romano A, Di Raimondo F.

Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC).

Oncotarget. 2016 Mar 7. doi: 10.18632/oncotarget.7969. [Epub ahead of print]

70. Vetro C, Rosso R, Palmucci S, Russello M, Colletta G, Romeo MA, Ximenes B, Romano A, [Palumbo GA](#), Di Raimondo F.

Erythrocytapheresis is a valid and safe therapeutic option in dysmetabolic iron overload syndrome.

J Clin Apher. 2015 Sep 28. doi: 10.1002/jca.21434. [Epub ahead of print]

69. Efficace F, Gaidano G, Breccia M, Voso MT, Cottone F, Angelucci E, Caocci G, Stauder R, Selleslag D, Sprangers M, Platzbecker U, Ricco A, Sanpaolo G, Beyne-Rauzy O, Buccisano F, [Palumbo GA](#), Bowen D, Nguyen K, Niscola P, Vignetti M, Mandelli F.

Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study.

Lancet Oncol. 2015 Sep 21. pii: S1470-2045(15)00206-5. doi: 10.1016/S1470-2045(15)00206-5. [Epub ahead of print]

68. Oliva EN, Lauseker M, Aloe Spiriti MA, Poloni A, Cortelezzi A, [Palumbo GA](#), Balleari E, Sanpaolo G, Volpe A, Ricco A, Ronco F, Alati C, D'Errigo MG, Santacaterina I, Kündgen A, Germing U, Latagliata R.

Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence.

Cancer Med. 2015 Sep 17. doi: 10.1002/cam4.523. [Epub ahead of print]

67. Caocci G, Voso MT, Angelucci E, Stauder R, Cottone F, Abel G, Nguyen K, Platzbecker U, Beyne-Rauzy O, Gaidano G, Invernizzi R, Molica S, Criscuolo M, Breccia M, Lübbert M, Sanpaolo G, Buccisano F, Ricco A, [Palumbo GA](#), Niscola P, Zhang H, Fenu S, La Nasa G, Mandelli F, Efficace F.

Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes.

Leuk Res. 2015 Jun 12. pii: S0145-2126(15)00184-8. doi: 10.1016/j.leukres.2015.05.012. [Epub ahead of print]

66. Savli H, Galimberti S, Sünnetçi D, Canesastraro M, Palumbo G, Nagy B, Di Raimondo F, Petrini M. **Bortezomib and Arsenic Trioxide (ATO) Activity on a Myelodysplastic Cell Line (P39): A Gene Expression Study.** Turk J Haematol. 2015 Apr 27. doi: 10.4274/tjh.2014.0058. [Epub ahead of print]
65. Rossi D, Brusca A, La Cava P, Galimberti S, Ciabatti E, Luminari S, Rigacci L, Tucci A, Pulsoni A, Bertoldo G, Vallisa D, Rusconi C, Spina M, Arcaini L, Angrilli F, Stelitano C, Merli F, Gaidano G, Federico M, Palumbo GA. **The genotype of MLH1 identifies a subgroup of follicular lymphoma patients that do not benefit from doxorubicin: FIL-FOLL05 study.** Haematologica. 2015 Jan 16. pii: haematol.2014.108183. [Epub ahead of print]
64. Romano A, Parrinello NL, Vetro C, Forte S, Chiarenza A, Figuera A, Motta G, Palumbo GA, Ippolito M, Consoli U, Raimondo FD. **Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy.** Br J Haematol. 2015 Mar;168(5):689-700. doi: 10.1111/bjh.13198. Epub 2014 Nov 7.
63. Galimberti S, Luminari S, Ciabatti E, Grassi S, Guerrini F, Dondi A, Marcheselli L, Ladetto M, Piccaluga PP, Gazzola A, Mannu C, Monitillo L, Mantoan B, Del Giudice I, Della Starza I, Cavalli M, Arcaini L, Tucci A, Palumbo GA, Rigacci L, Pulsoni A, Vitolo U, Boccomini C, Vallisa D, Bertoldo G, Gaidano G, Musto P, Petrini M, Federico M. **Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial.** Clin Cancer Res. 2014 Dec 15;20(24):6398-405. doi: 10.1158/1078-0432.CCR-14-0407. Epub 2014 Oct 14.
62. Vetro C, Romano A, Amico I, Conticello C, Motta G, Figuera A, Chiarenza A, Di Raimondo C, Giulietti G, Bonanno G, Palumbo GA, Di Raimondo F. **Endoscopic features of gastro-intestinal lymphomas: from diagnosis to follow-up.** World J Gastroenterol. 2014 Sep 28;20(36):12993-3005. doi: 10.3748/wjg.v20.i36.12993.
61. Efficace F, Gaidano G, Breccia M, Criscuolo M, Cottone F, Caocci G, Bowen D, Lübbert M, Angelucci E, Stauder R, Selleslag D, Platzbecker U, Sanpaolo G, Jonasova A, Buccisano F, Specchia G, Palumbo GA, Niscola P, Wan C, Zhang H, Fenu S, Klimek V, Beyne-Rauzy O, Nguyen K, Mandelli F. **Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes.** Br J Haematol. 2015 Feb;168(3):361-70. doi: 10.1111/bjh.13138. Epub 2014 Oct 1.
60. Giallongo C, Parrinello N, Tibullo D, La Cava P, Romano A, Chiarenza A, Barbagallo I, Palumbo GA, Stagno F, Vigneri P, Di Raimondo F. **Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients.** PLoS One. 2014 Jul 11;9(7):e101848. doi: 10.1371/journal.pone.0101848. eCollection 2014.
59. Romano A, Chiarenza A, Conticello C, Cavalli M, Vetro C, Di Raimondo C, Cunsolo R, Palumbo GA, Di Raimondo F. **Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients.** Eur J Haematol. 2014 Mar 27. doi: 10.1111/ejh.12325. [Epub ahead of print]
58. Neukirchen J, Lauseker M, Blum S, Giagounidis A, Lübbert M, Martino S, Siragusa S, Schlenk RF, Platzbecker U, Hofmann WK, Götze K, Palumbo GA, Magrin S, Kündgen A, Aul C, Hildebrandt B, Hasford J, Kobbe G, Haas R, Germing U. **Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study.** Leuk Res. 2014 Jan;38(1):57-64. doi: 10.1016/j.leukres.2013.10.013. Epub 2013 Oct 26.

57. Maffei R, Fiorcari S, Bulgarelli J, Rizzotto L, Martinelli S, Rigolin GM, Debbia G, Castelli I, Bonacorsi G, Santachiara R, Forconi F, Rossi D, Laurenti L, Palumbo GA, Vallisa D, Cuneo A, Gaidano G, Luppi M, Marasca R.

Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia.

Exp Hematol. 2014 Feb;42(2):126-136.e1. doi: 10.1016/j.exphem.2013.10.007. Epub 2013 Nov 6.

56. Giallongo C, La Cava P, Tibullo D, Barbagallo I, Parrinello N, Cupri A, Stagno F, Consoli C, Chiarenza A, Palumbo GA, Di Raimondo F.

SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation.

BMC Cancer. 2013 Feb 5;13:60. doi: 10.1186/1471-2407-13-60.

55. Romano A, Chiarenza A, Consoli U, Conticello C, Forte S, Uccello G, Vetro C, Cavalli M, Coppolino F, Palumbo GA, Di Raimondo F.

Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma.

Ann Oncol. 2013 Apr;24(4):1038-44. doi: 10.1093/annonc/mds531. Epub 2012 Nov 7.

54. Tibullo D, Barbagallo I, Giallongo C, La Cava P, Parrinello N, Vanella L, Stagno F, Palumbo GA, Li Volti G, Di Raimondo F.

Nuclear translocation of heme oxygenase-1 confers resistance to imatinib in chronic myeloid leukemia cells.

Curr Pharm Des. 2013;19(15):2765-70.

53. Oliva EN, Cuzzola M, Aloe Spiriti MA, Poloni A, Laganà C, Rigolino C, Morabito F, Galimberti S, Ghio R, Cortelezzi A, Palumbo GA, Sanpaolo G, Finelli C, Ricco A, Volpe A, Rodà F, Breccia M, Alimena G, Nobile F, Latagliata R.

Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study.

Ann Hematol. 2013 Jan;92(1):25-32. doi: 10.1007/s00277-012-1569-0. Epub 2012 Sep 16.

52. Galimberti S, Guerrini F, Salvi F, Petrini I, Gioia D, Messa E, Palumbo GA, Cilloni D, Petrini M, Levis A.

Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study.

J Hematol Oncol. 2012 Sep 10;5:53. doi: 10.1186/1756-8722-5-53.

51. Vetro C, Romano A, Chiarenza A, Conticello C, Donnarumma D, Gorgone A, Coppolino F, Palumbo GA, Bonanno G, Di Raimondo F

Endoscopic ultrasonography in gastric lymphomas: appraisal on reliability in long-term follow-up.

Hematol Oncol. 2011 Dec 20. doi: 10.1002/hon.1022. [Epub ahead of print]

50. Giallongo C, Tibullo D, La Cava P, Branca A, Parrinello N, Spina P, Stagno F, Conticello C, Chiarenza A, Vigneri P, Palumbo GA, Di Raimondo F.

BRIT1/MCPH1 Expression in Chronic Myeloid Leukemia and Its Regulation of the G2/M Checkpoint.

Acta Haematol. 2011;126(4):205-10. Epub 2011 Sep 16. Erratum in: Acta Haematol. 2011;126(4):210.

49. Dal Bo M, Rossi FM, Rossi D, Deambrogi C, Bertoni F, Del Giudice I, Palumbo G, Nanni M, Rinaldi A, Kwee I, Tissino E, Corradini G, Gozzetti A, Cencini E, Ladetto M, Coletta AM, Luciano F, Bulian P, Pozzato G, Laurenti L, Forconi F, Di Raimondo F, Marasca R, Del Poeta G, Gaidano G, Foà R, Guarini A, Gattei V.

13q14 Deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia.

Genes Chromosomes Cancer. 2011 Aug;50(8):633-43. doi: 10.1002/gcc.20885. Epub 2011 May 11.

48. Tibullo D, Barbagallo I, Giallongo C, La Cava P, Branca A, Conticello C, Stagno F, Chiarenza A, Palumbo GA, Di Raimondo F.

Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors.

Hematol Oncol. 2011 May 5. doi: 10.1002/hon.988. [Epub ahead of print]

47. Milone G, Poidomani M, Leotta S, Avola G, Camuglia MG, Privitera A, Consoli C, Mercurio S, Romeo MA, Di Marco A, Di Mercurio S, Spadaro A, Palumbo GA, Tedeschi P.

Prognostic value of CD34+ peak in peripheral blood during mobilization in intermediate-risk AML patients treated in first CR by autologous or allogeneic transplantation.

Bone Marrow Transplant. 2012 Jan;47(1):24-32. doi: 10.1038/bmt.2011.33. Epub 2011 Mar 14.

46. Giallongo C, La Cava P, Tibullo D, Parrinello N, Barbagallo I, Del Fabro V, Stagno F, Conticello C, Romano A, Chiarenza A, Palumbo GA, Di Raimondo F.

Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells.

Eur J Haematol. 2011 Mar;86(3):216-25. doi: 10.1111/j.1600-0609.2010.01570.x. Epub 2011 Feb 8.

45. Galimberti S, Canestraro M, Savli H, Palumbo GA, Tibullo D, Nagy B, Piaggi S, Guerrini F, Cine N, Metelli MR, Petrini M.

ITF2357 interferes with apoptosis and inflammatory pathways in the HL-60 model: a gene expression study.

Anticancer Res. 2010 Nov;30(11):4525-35.

44. Barresi V, Romano A, Musso N, Capizzi C, Consoli C, Martelli MP, Palumbo G, Di Raimondo F, Condorelli DF.

Broad copy neutral-loss of heterozygosity regions and rare recurring copy number abnormalities in normal karyotype-acute myeloid leukemia genomes.

Genes Chromosomes Cancer. 2010 Nov;49(11):1014-23.

43. Barresi V, Palumbo GA, Musso N, Consoli C, Capizzi C, Meli CR, Romano A, Di Raimondo F, Condorelli DF.

Clonal selection of 11q CN-LOH and CBL gene mutation in a serially studied patient during MDS progression to AML.

Leuk Res. 2010 Nov;34(11):1539-42. Epub 2010 Aug 1.

42. Canestraro M, Galimberti S, Savli H, Palumbo GA, Tibullo D, Nagy B, Guerrini F, Piaggi S, Cine N, Metelli MR, Petrini M.

Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders.

Cancer Genet Cytogenet. 2010 Jun;199(2):110-20.

41. Galimberti S, Nagy B, Palumbo GA, Ciancia E, Buda G, Orciuolo E, Melosi A, Lambelet P, Ronca F, Petrini M.

Vascular endothelial growth factor polymorphisms in mantle cell lymphoma.

Acta Haematol. 2010;123(2):91-5. Epub 2009 Dec 19.

40. Barbagallo I, Vanella A, Peterson SJ, Kim DH, Tibullo D, Giallongo C, Vanella L, Parrinello N, Palumbo GA, Raimondo FD, Abraham NG, Asprinio D.

Overexpression of heme oxygenase-1 increases human osteoblast stem cell differentiation.

J Bone Miner Metab. 2010 May;28(3):276-88. Epub 2009 Nov 19.

39. Di Pietro C, Ragusa M, Barbagallo D, Duro LR, Guglielmino MR, Majorana A, Angelica R, Scalia M, Statello L, Salito L, Tomasello L, Pernagallo S, Valenti S, D'Agostino V, Triberio P, Tandurella I, Palumbo GA, La Cava P, Cafiso V, Bertuccio T, Santagati M, Li Destri G, Lanzafame S, Di Raimondo F, Stefani S, Mishra B, Purrello M.

The apoptotic machinery as a biological complex system: analysis of its omics and evolution, identification of candidate genes for fourteen major types of cancer, and experimental validation in CML and neuroblastoma.

BMC Med Genomics. 2009 Apr 30;2(1):20.

38. Tibullo D, Giallongo C, La Cava P, Berretta S, Stagno F, Chiarenza A, Conticello C, Palumbo GA, Di Raimondo F.

Effects of imatinib mesylate in osteoblastogenesis.

Exp Hematol. 2009 Apr;37(4):461-8.

37. Leidi M, Gotti E, Bologna L, Miranda E, Rimoldi M, Sica A, Roncalli M, Palumbo GA, Introna M, Golay J. **M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro.**

J Immunol. 2009 Apr 1;182(7):4415-22.

36. Palumbo GA, Parrinello N, Fargione G, Cardillo K, Chiarenza A, Berretta S, Conticello C, Villari L, Di Raimondo F.

CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia.

Leuk Res. 2009 Sep;33(9):1212-6. Epub 2009 Feb 20.

35. Conticello C, Adamo L, Vicari L, Giuffrida R, Iannolo G, Anastasi G, Caruso L, Moschetti G, Cupri A, Palumbo GA, Gulisano M, De Maria R, Giustolisi R, Di Raimondo F.

Antitumor activity of bortezomib alone and in combination with TRAIL in human acute myeloid leukemia.

Acta Haematol. 2008;120(1):19-30. Epub 2008 Aug 21.

34. Barbagallo I, Tibullo D, Di Rosa M, Giallongo C, Palumbo GA, Raciti G, Campisi A, Vanella A, Green CJ, Motterlini R.

A cytoprotective role for the heme oxygenase-1/CO pathway during neural differentiation of human mesenchymal stem cells.

J Neurosci Res. 2008 Jul;86(9):1927-35.

33. Carlotti E, Palumbo GA, Oldani E, Tibullo D, Salmoiraghi S, Rossi A, Golay J, Pulsoni A, Foa R, Rambaldi A.

FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab.

Haematologica. 2007 Aug;92(8):1127-30.

32. Galimberti S, Palumbo GA, Caracciolo F, Benedetti E, Pelosini M, Brizzi S, Ciabatti E, Fazzi R, Stelitano C, Quintana G, Conte E, Tibullo D, Di Raimondo F, Petrini M.

The efficacy of rituximab plus Hyper-CVAD regimen in mantle cell lymphoma is independent of FCgammaRIIIa and FCgammaRIIa polymorphisms.

J Chemother. 2007 Jun;19(3):315-21.

31. Di Raimondo F, Caruso L, Bonanno G, Naso P, Chiarenza A, Fiumara P, Bari A, Palumbo G, Russo A, Giustolisi R.

Is endoscopic ultrasound clinically useful for follow-up of gastric lymphoma?

Ann Oncol. 2007 Feb;18(2):351-6. Epub 2006 Oct 25.

30. Di Raimondo F, Pennisi A, Bari A, Fiumara P, Palumbo GA.

Management of multiple myeloma.

G Ital Nefrol. 2005 Nov-Dec;22 Suppl 33:S46-52.

29. Malaguarnera L, Pilastro MR, Vicari L, Dimarco R, Manzella L, Palumbo G, Messina A.

Pyrrrolidinedithiocarbamate induces apoptosis in human acute myelogenous leukemic cells affecting NF-kappaB activity.

Cancer Invest. 2005;23(5):404-12.

28. Galimberti S, Guerrini F, Palumbo GA, Consoli U, Fazzi R, Morabito F, Santini V, Petrini M.

Evaluation of BCRP and MDR-1 co-expression by quantitative molecular assessment in AML patients.

Leuk Res. 2004 Apr;28(4):367-72.

27. Santonocito AM, Consoli U, Bagnato S, Milone G, Palumbo GA, Di Raimondo F, Stagno F, Guglielmo P, Giustolisi R.
Flow cytometric detection of aneuploid CD38(++) plasmacells and CD19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients.
Leuk Res. 2004 May;28(5):469-77.
26. Galimberti S, Guerrini F, Carulli G, Fazzi R, Palumbo GA, Morabito F, Petrini M.
Significant co-expression of WT1 and MDR1 genes in acute myeloid leukemia patients at diagnosis.
Eur J Haematol. 2004 Jan;72(1):45-51.
25. Galimberti S, Rossi A, Palumbo GA, Morabito F, Guerrini F, Vincelli I, Fazzi R, Santini V, Petrini M.
FLT3 mutations do not influence MDR-1 gene expression in acute myeloid leukemia.
Anticancer Res. 2003 Jul-Aug;23(4):3419-26.
24. Galimberti S, Guerrini F, Morabito F, Palumbo GA, Di Raimondo F, Papineschi F, Caracciolo F, Fazzi R, Cervetti G, Cuzzocrea A, Petrini M.
Quantitative molecular evaluation in autotransplant programs for follicular lymphoma: efficacy of in vivo purging by Rituximab.
Bone Marrow Transplant. 2003 Jul;32(1):57-63.
23. Galimberti S, Morabito F, Guerrini F, Palumbo GA, Azzara A, Martino M, Benedetti E, Di Raimondo F, Petrini M.
Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients.
Br J Haematol. 2003 Feb;120(3):405-12.
22. Milone G, Di Raimondo F, Gioi FL, Palumbo GA, Manenti GO, Pafumi M, Giustolisi R.
Alternation of epirubicin and mitoxantrone in CHOP-like regimens retains efficacy and reduces overall toxicity in elderly patients with high and intermediate grade non-Hodgkin lymphomas.
Leuk Lymphoma. 2002 Dec;43(12):2319-24.
21. Consoli U, Milone G, Guido G, Consoli C, Palumbo GA, Giustolisi R.
STI571 (GLIVEC) induced hematologic, cytogenetic and molecular remission in a CML patient relapsing with accelerated phase after allogeneic stem cell transplantation.
Haematologica. 2002 Dec;87(12):ECR37.
20. Consoli U, Santonocito A, Stagno F, Fiumara P, Privitera A, Parisi G, Giustolisi GM, Pavone B, Palumbo GA, Di Raimondo F, Milone G, Guglielmo P, Giustolisi R.
Multidrug resistance mechanisms in chronic lymphocytic leukaemia.
Br J Haematol. 2002 Mar;116(4):774-80.
19. Di Raimondo F, Palumbo GA, Molica S, Giustolisi R.
Angiogenesis in chronic myeloproliferative diseases.
Acta Haematol. 2001;106(4):177-83. Review.
18. Di Raimondo F, Azzaro MP, Palumbo GA, Bagnato S, Stagno F, Giustolisi GM, Cacciola E, Sortino G, Guglielmo P, Giustolisi R.
Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis.
Leukemia. 2001 Jun;15(6):976-80.
17. Shteper PJ, Siegfried Z, Asimakopoulos FA, Palumbo GA, Rachmilewitz EA, Ben-Neriah Y, Ben-Yehuda D.
ABL1 methylation in Ph-positive ALL is exclusively associated with the P210 form of BCR-ABL.
Leukemia. 2001 Apr;15(4):575-82.
16. Di Raimondo F, Palumbo GA, Azzaro MP, Giustolisi R.
Angiogenesis in acute myeloid leukemia.

Blood. 2000 Nov 15;96(10):3656-7.

15. Stagno F, Guglielmo P, Consoli U, Inghilterra G, Giustolisi GM, Palumbo GA, Giustolisi R.
In vitro apoptotic response of freshly isolated chronic myeloid leukemia cells to all-trans retinoic acid and cytosine arabinoside.

Acta Haematol. 2000;104(2-3):57-64.

14. Di Raimondo F, Azzaro MP, Palumbo G, Bagnato S, Giustolisi G, Florida P, Sortino G, Giustolisi R.
Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.

Haematologica. 2000 Aug;85(8):800-5.

13. Aksentijevich I, Torosyan Y, Samuels J, Centola M, Pras E, Chae JJ, Oddoux C, Wood G, Azzaro MP, Palumbo G, Giustolisi R, Pras M, Ostrer H, Kastner DL.

Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population.

Am J Hum Genet. 1999 Apr;64(4):949-62.

12. Ben-Yehuda D, Krichevsky S, Rachmilewitz EA, Avraham A, Palumbo GA, Frassoni F, Sahar D, Rosenbaum H, Paltiel O, Zion M, Ben-Neriah Y.

Molecular follow-up of disease progression and interferon therapy in chronic myelocytic leukemia.

Blood. 1997 Dec 15;90(12):4918-23.

11. Palumbo GA, Yarom N, Gazit A, Sandalon Z, Baniyash M, Kleinberger-Doron N, Levitzki A, Ben-Yehuda D.

The tyrphostin AG17 induces apoptosis and inhibition of cdk2 activity in a lymphoma cell line that overexpresses bcl-2.

Cancer Res. 1997 Jun 15;57(12):2434-9.

10. Di Raimondo F, Palumbo GA, Romeo MA, Galvagno F, Stagno F, Morabito F, Giustolisi R.

Evaluation of Taxol cytotoxicity on B-CLL cells in vitro.

Leuk Lymphoma. 1997 Jun;26(1-2):115-9.

9. Palumbo GA, Romeo MA, Di Raimondo F, Giustolisi R.

Interferon enhanced minimal residual disease detection in acute promyelocytic leukaemia.

Br J Haematol. 1997 Mar;96(4):876-7.

8. Di Raimondo F, Longo G, Cacciola E Jr, Milone G, Palumbo GA, Cacciola RR, Alessi M, Giustolisi R.

A good response rate to recombinant erythropoietin alone may be expected in selected myelodysplastic patients. A preliminary clinical study.

Eur J Haematol. 1996 Jan-Feb;56(1-2):7-11.

7. Di Raimondo F, Palumbo GA, Romeo MA, Cacciola E, Milone G, Impera S, Giustolisi R, Cacciola E.

In vitro sensitivity of B-CLL cells to fludarabine and interferons.

Leuk Lymphoma. 1995 May;17(5-6):449-53.

6. Tedeschi A, Palumbo G, Milazzo N, Miadonna A.

Nasal neutrophilia and eosinophilia induced by challenge with platelet activating factor.

J Allergy Clin Immunol. 1994 Feb;93(2):526-33.

5. Morale MC, Guarcello V, Bartoloni G, Raiti F, Cutuli N, Palumbo G Jr, Farinella Z, Marchetti B.

Peptidergic modulation of immune system development: role of luteinizing hormone-releasing hormone.

Pharmacol Res. 1990 Sep-Oct;22 Suppl 1:97-8.

4. Palumbo G Jr, Morale MC, Guarcello V, Cutuli N, Raiti F, Farinella Z, Marchetti B.

Neuroendocrine modulation of lymphocyte's activity during the physiological menstrual cycle.

Pharmacol Res. 1990 Sep-Oct;22 Suppl 1:101-2.

3. Marchetti B, Guarcello V, Morale MC, Bartoloni G, Palumbo G Jr, Raiti F, Cutuli N, Farinella Z, Scapagnini U.

A physiological role for the neuropeptide luteinizing hormone-releasing hormone (LHRH) during the maturation of thymus gland function.

Int J Neurosci. 1990 Apr;51(3-4):287-9.

2. Marchetti B, Morale MC, Guarcello V, Cutuli N, Raiti F, Batticane N, Palumbo G Jr, Farinella Z, Scapagnini U.

Cross-talk communication in the neuroendocrine-reproductive-immune axis. Age-dependent alterations in the common communication networks.

Ann N Y Acad Sci. 1990;594:309-25. Review.

1. Marchetti B, Guarcello V, Morale MC, Bartoloni G, Raiti F, Palumbo G Jr, Farinella Z, Cordaro S, Scapagnini U.

Luteinizing hormone-releasing hormone (LHRH) agonist restoration of age-associated decline of thymus weight, thymic LHRH receptors, and thymocyte proliferative capacity.

Endocrinology. 1989 Aug;125(2):1037-45.

MONOGRAPHS

5. Romano A., Barresi V., Consoli C., Musso N., Capizzi C., Palumbo G.A., Di Raimondo F. and Condorelli D.F.

Conventional and molecular cytogenetic techniques and their application in Myelodysplastic Syndromes.

In Myelodysplastic Syndromes: From Pathogenesis to Diagnosis and Therapy- Chapter 6, NOVA Publishers, ISBN 978-1-62417-580-0, edited by Hamid Sayar (Indiana University Simon Cancer Center, Indianapolis, IN, USA)

4. Palumbo G.A.

Splenomegalie.

In Bosi A., De Stefano V., Di Raimondo F., La Nasa G MANUALE DI MALATTIE DEL SANGUE, 2012, Elsevier, ISBN: 9788821432620.

3. Palumbo G.A., Vetro C., Di Raimondo F.

Linfomi.

In Bosi A., De Stefano V., Di Raimondo F., La Nasa G MANUALE DI MALATTIE DEL SANGUE, 2012, Elsevier, ISBN: 9788821432620.

2. Vetro C., Romano A., Palumbo G.A., Bonanno G. and Di Raimondo F.

Role of the Endoscopic Ultrasonography in the Management of Gastric Lymphomas: Our Experience and Review of Literature.

In Ultrasound Imaging - Medical Applications ISBN 978-953-307-279-1, Edited by: Igor V. Minin and Oleg V. Minin, InTech (2011)

1. Palumbo G.A., Cacciola E., Guglielmo P., Giustolisi R., Cacciola E. (1994). **Relationship between growth factors, oncogenes and cytokines in the mechanism of aberrant hematopoiesis.**

In Cacciola E., Deisseroth A.B., Giustolisi R. (Eds.): HEMOPOIETIC GROWTH FACTORS, ONCOGENES AND CYTOKINES IN CLINICAL HEMATOLOGY. Basel, Karger, 1994, pp. 1-21.

IN EXTENSO COOPERATION PAPERS INDEXED IN MEDLINE

2. Musto P, Maurillo L, Spagnoli A, Gozzini A, Rivellini F, Lunghi M, Villani O, Aloe-Spiriti MA, Venditti A, Santini V; Ad Hoc Italian Cooperative Study Group on Azacitidine in Myelodysplastic Syndromes Acute Leukemias.

Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program.


Cancer. 2010 Mar 15;116(6):1485-94.

1. Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A, Pulsoni A, Musso M, Liberati AM, Olivieri A, Gallamini A, Pogliani E, Scalabrini DR, Callea V, Di Raimondo F, Pavone V, Tucci A, Cortelazzo S, Levis A, Boccadoro M, Majolino I, Pileri A, Gianni AM, Passera R, Corradini P, Tarella C; Gruppo Italiano Trapianto di Midollo Osseo (GITMO); Intergruppo Italiano Linfomi (IIL).

Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage.

Blood. 2008 Apr 15;111(8):4004-13. Epub 2008 Jan 31.

31ST OF DECEMBER, 2022

A handwritten signature in black ink, appearing to be 'Enrico Pileri', written in a cursive style.